Q1 Earnings Forecast for ACAD Issued By HC Wainwright

ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) – HC Wainwright issued their Q1 2026 earnings per share (EPS) estimates for shares of ACADIA Pharmaceuticals in a research note issued on Thursday, November 6th. HC Wainwright analyst A. Fein expects that the biopharmaceutical company will post earnings per share of $0.12 for the quarter. The consensus estimate for ACADIA Pharmaceuticals’ current full-year earnings is $0.70 per share. HC Wainwright also issued estimates for ACADIA Pharmaceuticals’ Q2 2026 earnings at $0.20 EPS, Q3 2026 earnings at $0.24 EPS, FY2027 earnings at $2.54 EPS, FY2028 earnings at $2.74 EPS and FY2029 earnings at $2.89 EPS.

Several other analysts have also issued reports on the stock. Needham & Company LLC upped their price target on shares of ACADIA Pharmaceuticals from $28.00 to $29.00 and gave the stock a “buy” rating in a research report on Thursday. The Goldman Sachs Group lifted their price objective on shares of ACADIA Pharmaceuticals from $15.00 to $17.00 and gave the company a “sell” rating in a research report on Thursday, August 7th. Citigroup began coverage on shares of ACADIA Pharmaceuticals in a report on Tuesday, October 21st. They issued a “buy” rating and a $33.00 target price on the stock. Weiss Ratings reiterated a “hold (c)” rating on shares of ACADIA Pharmaceuticals in a research note on Tuesday, October 14th. Finally, Mizuho boosted their price target on ACADIA Pharmaceuticals from $23.00 to $24.00 and gave the stock a “neutral” rating in a research report on Thursday, August 7th. One investment analyst has rated the stock with a Strong Buy rating, twelve have given a Buy rating, six have assigned a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat.com, ACADIA Pharmaceuticals presently has an average rating of “Moderate Buy” and an average price target of $28.94.

ACADIA Pharmaceuticals Trading Down 0.0%

Shares of NASDAQ:ACAD traded down $0.01 during trading on Friday, hitting $21.64. 203,297 shares of the company were exchanged, compared to its average volume of 2,152,439. ACADIA Pharmaceuticals has a fifty-two week low of $13.40 and a fifty-two week high of $26.65. The firm has a fifty day moving average price of $22.69 and a two-hundred day moving average price of $21.84. The stock has a market cap of $3.65 billion, a price-to-earnings ratio of 16.32, a P/E/G ratio of 7.90 and a beta of 0.80.

ACADIA Pharmaceuticals (NASDAQ:ACAD) last released its earnings results on Wednesday, November 5th. The biopharmaceutical company reported $0.42 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.14 by $0.28. ACADIA Pharmaceuticals had a return on equity of 14.69% and a net margin of 21.80%.The business had revenue of $278.63 million for the quarter, compared to analyst estimates of $276.52 million. During the same quarter in the prior year, the company posted $0.20 earnings per share. ACADIA Pharmaceuticals’s revenue was up 11.3% on a year-over-year basis. ACADIA Pharmaceuticals has set its FY 2025 guidance at EPS.

Insiders Place Their Bets

In other news, EVP Mark C. Schneyer sold 3,498 shares of ACADIA Pharmaceuticals stock in a transaction on Monday, September 15th. The stock was sold at an average price of $23.65, for a total transaction of $82,727.70. Following the completion of the sale, the executive vice president owned 43,447 shares of the company’s stock, valued at approximately $1,027,521.55. This trade represents a 7.45% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, Director Elizabeth A. Garofalo sold 1,600 shares of the stock in a transaction that occurred on Tuesday, September 2nd. The stock was sold at an average price of $25.98, for a total transaction of $41,568.00. Following the transaction, the director owned 25,382 shares in the company, valued at approximately $659,424.36. The trade was a 5.93% decrease in their position. The disclosure for this sale is available in the SEC filing. Insiders have sold 27,098 shares of company stock valued at $678,256 in the last three months. Insiders own 26.50% of the company’s stock.

Hedge Funds Weigh In On ACADIA Pharmaceuticals

A number of hedge funds have recently added to or reduced their stakes in the stock. Geneos Wealth Management Inc. lifted its position in shares of ACADIA Pharmaceuticals by 113.0% during the 3rd quarter. Geneos Wealth Management Inc. now owns 1,425 shares of the biopharmaceutical company’s stock valued at $30,000 after acquiring an additional 756 shares during the period. Banque Transatlantique SA acquired a new position in ACADIA Pharmaceuticals in the first quarter valued at about $31,000. Picton Mahoney Asset Management bought a new stake in ACADIA Pharmaceuticals during the first quarter worth about $32,000. Smartleaf Asset Management LLC grew its stake in ACADIA Pharmaceuticals by 107.0% during the third quarter. Smartleaf Asset Management LLC now owns 1,712 shares of the biopharmaceutical company’s stock worth $36,000 after buying an additional 885 shares in the last quarter. Finally, Federated Hermes Inc. increased its holdings in ACADIA Pharmaceuticals by 231.5% in the 1st quarter. Federated Hermes Inc. now owns 2,317 shares of the biopharmaceutical company’s stock valued at $38,000 after buying an additional 1,618 shares during the period. Institutional investors own 96.71% of the company’s stock.

ACADIA Pharmaceuticals Company Profile

ACADIA Pharmaceuticals Inc, a biopharmaceutical company, focuses on the development and commercialization innovative medicines that address unmet medical needs in central nervous system (CNS) disorders and rare diseases in the United States. The company offers NUPLAZID (pimavanserin) for the treatment of hallucinations and delusions associated with Parkinson's disease psychosis; and DAYBUE, a novel synthetic analog of the amino-terminal tripeptide of insulin-like growth factor 1 for treatment of Rett Syndrome.